Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Matelda Zancan"'
Autor:
Antonio Scapinello, Valentina Agnolon, Claudio Ceccarelli, Silvia Michilin, Lucia Peloso, Matelda Zancan, Aline S.C. Fabricio, Massimo Gion, Ruggero Dittadi
Publikováno v:
Scandinavian journal of clinical and laboratory investigation. 79(4)
The aim of the present study was to investigate serum HER2 extracellular domain (ECD) as a putative surrogate marker of the shedding phenomenon of HER2 receptor from the tumor tissue of primary breast cancer (BC) patients. A pilot retrospective study
Autor:
Giulia Rainato, Aline S.C. Fabricio, Andrea Fandella, Vincenzo Scattoni, Matelda Zancan, Massimo Gion, Lucia Peloso, Ruggero Dittadi, M Barichello
Publikováno v:
The International Journal of Biological Markers. 31:317-323
Background Prostate-specific antigen (PSA) lacks specificity and sensitivity in discriminating prostate cancer (PCa) from benign prostatic hyperplasia (BPH) when the total PSA (tPSA) level is between 4 and 10 ng/mL. It remains to be investigated if a
Autor:
Marco Agostini, C. Pianon, Francesca Malentacchi, Massimo Gion, Paola Del Bianco, Claudio Orlando, Bruno Murer, Matelda Zancan, Francesca Galdi, Fulvio Di Tonno, C. Mazzariol, Aline S.C. Fabricio, Michela Maran
Publikováno v:
The International Journal of Biological Markers. 24:147-155
The diagnosis and follow-up of bladder cancer are mainly based on cystoscopy, an invasive method which could be negative in case of flat malignancies such as carcinoma in situ. Other noninvasive diagnostic methods have not yet given satisfactory resu
Publikováno v:
The International Journal of Biological Markers. 16:255-261
Serum HER-2/neu concentrations were evaluated in 172 healthy subjects, 176 primary and 55 metastatic breast cancer patients, employing a new automated assay (Bayer Immuno 1™ serum HER-2/neu). Using 13 ng/mL as the cutoff, abnormal HER-2/neu serum l
Autor:
Angelo, Paradiso, Anita, Mangia, Claudio, Orlando, Paolo, Verderio, Maurizio, Belfiglio, Antonio, Marchetti, Lucio, Bertario, Gennaro, Chiappetta, Massimo, Gion, Gian Paolo, Tonini, Franca, Podo, Amina, Vocaturo, Rosella, Silvestrini, Massimo, Romani, Elena, Belloni, Delia, Cavallo, Paola, Ulivi, Stefania, Tommasi, Agostino, Steffan, Antonio, Russo, Massimo, Alessio, Daniele, Calistri, Matelda, Zancan, Paola, Parrela, Massimo, Broggini, Antonio, Giuseppe, Fiamma, Buttitta, Gaetano, Finocchiaro, Katia, Mazzocco, Giulia, Veronesi, Lorena, Landuzzi, Maria, Benevolo, Luciano, Mariani, Federico, De Marco, Aldo, Venuti, Gianluigi, Giannelli, Michele, Quaranta, Vito, Trojano
Publikováno v:
Scopus-Elsevier
In 2007, an Italian cancer research group proposed a specific concerted action aimed at the “analytical and clinical validation of new biomarkers for early diagnosis: Network, resources, methodology, quality control, and data analysis.” The propo
Autor:
Rafael Molina, Massimo Gion, Axel Gressner, Frédéric Troalen, Jose Maria Auge, Stefan Holdenrieder, Matelda Zancan, Matthias Wycislo, Petra Stieber
Publikováno v:
Clinical Chemistry and Laboratory Medicine. 46
Autor:
Stefan, Holdenrieder, Rafael, Molina, Massimo, Gion, Axel, Gressner, Frédéric, Troalen, Jose Maria, Auge, Matelda, Zancan, Matthias, Wycislo, Petra, Stieber
Publikováno v:
Clinical Chemistry and Laboratory Medicine. 46
Cancer antigen CA125 is known as a valuable marker for the management of ovarian cancer.The analytical and clinical performance of the Access OV Monitor Immunoassay System (Beckman Coulter) was evaluated at five different European sites and compared
Autor:
Petra Stieber, Rafael Molina, Massimo Gion, Axel Gressner, Frédéric Troalen, Stefan Holdenrieder, Jose Maria Auge, Matelda Zancan, Matthias Wycislo, Véronique Jarrige
Publikováno v:
Clinical Chemistry and Laboratory Medicine. 46
Background: Cancer antigen CA15-3 antigen is known as a valuable marker for the management of breast cancer. Methods: The analytical and clinical performance of the Access' BR Monitor Immunoassay System (Beckman Coulter) was evaluated at five differe
Autor:
Dino Amadori, Francesco Cognetti, Antonio Lambiase, Matelda Zancan, Paola Papaldo, Diana Crivellari, Massimo Gion, Alessandro Morabito, Luigi Mariani, Giampietro Gasparini, Francesco Torino, Antonella Spada, Antonio Caputo, Livia De Sio, Vittorio Silingardi, Gianfranco Filippelli
Publikováno v:
Breast cancer research and treatment. 101(3)
A randomized Phase II study evaluated the activity of weekly paclitaxel versus its combination with trastuzumab for treatment of patients with advanced breast cancer overexpressing HER-2.Among 124 patients randomized, 123 are assessable for toxicity
Autor:
C. Mimmo, M. Vianello, G. Malossini, Matelda Zancan, F. Di Tonno, R. Franceschini, C. Mazzariol, Massimo Gion
Publikováno v:
The International journal of biological markers. 20(2)
The aim of the present preliminary study was to investigate the presence of free DNA (FDNA) in urine as a possible marker for the diagnosis of bladder cancer. Naturally voided morning urine specimens were collected from 57 patients with suspected bla